What is XtalPi?
Founded in 2014, XtalPi operates at the vanguard of the digital biology revolution. The company utilizes proprietary AI-driven platforms to simulate and predict the physical and chemical properties of drug candidates, significantly reducing the time and cost associated with traditional laboratory experimentation. By transforming the drug development process into a data-centric discipline, XtalPi enables its partners to navigate complex molecular landscapes with unprecedented precision. This market position is bolstered by a robust intellectual property portfolio and a strategic focus on high-throughput screening, positioning the firm as an essential infrastructure provider for the next generation of therapeutic innovation.
How much funding has XtalPi raised?
XtalPi has raised a total of $784.8M across 4 funding rounds:
Series A
$5M
Series C
$318.8M
Series B
$61M
Series D
$400M
Series A (2015): $5M with participation from Tencent
Series C (2020): $318.8M led by The Morningside Group, PICC Capital, and SoftBank Vision Fund 2
Series B (2021): $61M supported by GV, BGF, Sequoia China, Tencent, Yael Capital, and China Life Healthcare Fund
Series D (2021): $400M featuring HOPU Investment Management Co. and OrbiMed Healthcare Fund Management
Key Investors in XtalPi
GV
GV is a venture capital firm that invests across multiple stages and sectors, focusing on enterprise solutions, life sciences, and frontier technology innovations.
Tencent
Tencent is a global technology company that invests in technology innovation and supports developers through a broad ecosystem of digital platforms and enterprise solutions.
HOPU Investment Management Co.
HOPU Investment Management is a firm operating in the investment banking sector, providing strategic capital to support growth-stage enterprises.
What's next for XtalPi?
With the recent influx of capital, XtalPi is well-positioned to scale its computational infrastructure and expand its collaborative footprint within the global life sciences ecosystem. The company is expected to prioritize the enhancement of its predictive modeling capabilities, potentially integrating deeper machine learning architectures to address more complex biological targets. As the firm matures, the focus will likely shift toward deepening its strategic alliances with major pharmaceutical conglomerates, further embedding its technology into the standard operating procedures of global drug development. This growth phase will be critical in determining the company's long-term impact on the efficiency and success rates of clinical-stage drug candidates.
See full XtalPi company page
